BRIEF-Kazia Therapeutics Provides Update On Paxalisib Regulatory Pathway Following Type C Meeting With FDA
ReutersDec 31, 2024 1:54 PM
Dec 31 (Reuters) - Kazia Therapeutics Ltd KZIA.O:
KAZIA THERAPEUTICS PROVIDES UPDATE ON PAXALISIB REGULATORY PATHWAY FOLLOWING TYPE C MEETING WITH FDA
KAZIA THERAPEUTICS LTD - FDA SAYS OS DATA NOT APPROPRIATE FOR ACCELERATED APPROVAL
KAZIA THERAPEUTICS LTD - FDA COMMENTS OS DATA SUPPORTIVE FOR PIVOTAL REGISTRATIONAL STUDY
KAZIA THERAPEUTICS LTD - ALIGNS WITH FDA ON PHASE 3 STUDY DESIGN
Source text: ID:nPn5mLr4Da
Further company coverage: KZIA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Related Articles
Can Palantir Stock Be a Big Winner For Investors Again in 2025?
TradingKey - Any investor who had a stake in large cap Artificial Intelligence (AI) stocks in 2024 probably did pretty well. That was down to the fact that the thematic powered the US stock market higher last year, with the S&P 500 Index ending the year up 23.3%.TradingKey
Fri, Jan 3
1 Stock To Buy for the Renewable Energy Revolution
TradingKey - When we talk about renewable energy and the boom in demand for cleaner sources of fuel, many investors may think the biggest winners are companies involved in electric vehicles (EVs) or solar panel production.TradingKey
Fri, Jan 3
What to Expect at CES 2025
TradingKey - As a barometer for the tech economy, CES 2025 is set to kick off on January 5 in Las Vegas, reaffirming its position as one of the world's largest tech exhibitions.TradingKey
Fri, Jan 3
